Back

Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancer

Bras, A. R.; Lopes, A.; Mendes, N.; Costa, P. J.; Ferreira, A.; Granja, S.; Silva, A. P.; Tortosa, F.; Baltazar, F.; Gartner, F.; Sousa, M. J.; Valente, A.; Preto, A.

2023-08-13 pharmacology and toxicology
10.1101/2023.08.09.552513 bioRxiv
Show abstract

KRAS hotspot mutations are difficult to target, highlighting the need of developing new specific target drugs for cancers driven by these mutations, like colorectal cancer (CRC). Here, we discover a new ruthenium compound, PMC79, that inhibits specifically mutated KRAS and the downstream signaling ERK and AKT proteins both "in vitro" and "in vivo". We demonstrated that PMC79 inhibits KRAS mutated kinase activity and is selective for KRAS mutations not affecting the KRAS wild-type protein. KRAS inhibition is not dependent on actin polymerization or on proteasome. Molecular docking analysis suggests that this effect might result from protein dynamics associated with the mutations. We demonstrated that low doses of PMC79 potentiate 5-fluorouracil anticancer effect. "In vivo" PMC79 "proof of concept" showed that it reduces tumor growth in the CAM-xenograft model and induces necrosis of the tumor in the xenograft mice model. PMC79 is a promising new "magic bullet" for CRCs harboring mutated KRAS.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Scientific Reports
○ 3612 papers in training set
Top 2%
12.9%
Similar papers in this journal
2
Journal of Medicinal Chemistry
● 77 papers in training set
Top 0.1%
11.9%
Similar papers in this journal
3
Frontiers in Pharmacology
○ 111 papers in training set
Top 0.2%
7.9%
Similar papers in this journal
4
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.1%
6.7%
Similar papers in this journal
5
ACS Pharmacology & Translational Science
● 40 papers in training set
Top 0.1%
4.8%
Similar papers in this journal
6
Pharmaceuticals
○ 34 papers in training set
Top 0.2%
3.2%
7
International Journal of Molecular Sciences
○ 494 papers in training set
Top 4%
3.2%
50% of probability mass above
8
PLOS ONE
● 5266 papers in training set
Top 36%
3.2%
9
Acta Pharmaceutica Sinica B
○ 11 papers in training set
Top 0.1%
3.2%
10
eLife
● 5828 papers in training set
Top 42%
2.4%
11
ChemMedChem
○ 16 papers in training set
Top 0.1%
2.4%
12
Molecules
○ 39 papers in training set
Top 0.4%
2.4%
13
European Journal of Medicinal Chemistry
○ 17 papers in training set
Top 0.1%
2.4%
14
Pharmacological Research
○ 18 papers in training set
Top 0.1%
2.0%
15
Biochemical Pharmacology
○ 20 papers in training set
Top 0.2%
1.7%
16
Cancers
○ 213 papers in training set
Top 3%
1.7%
17
European Journal of Pharmacology
○ 15 papers in training set
Top 0.2%
1.7%
18
ACS Omega
● 105 papers in training set
Top 1%
1.7%
19
Heliyon
○ 152 papers in training set
Top 4%
1.3%
20
Nature Communications
○ 5641 papers in training set
Top 50%
1.1%
21
Oncotarget
○ 18 papers in training set
Top 0.3%
1.0%
22
Molecular Pharmaceutics
● 16 papers in training set
Top 0.3%
1.0%
23
Communications Biology
○ 993 papers in training set
Top 26%
1.0%
24
ACS Infectious Diseases
● 82 papers in training set
Top 2%
0.8%
25
Computational and Structural Biotechnology Journal
● 242 papers in training set
Top 7%
0.8%
26
Frontiers in Oncology
○ 103 papers in training set
Top 4%
0.6%
27
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 2%
0.6%
28
BMC Cancer
○ 67 papers in training set
Top 2%
0.6%
29
Journal of Biomolecular Structure and Dynamics
○ 43 papers in training set
Top 1%
0.6%
30
Cell Reports
○ 1498 papers in training set
Top 29%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.